TOP TEN perturbations for NM_000144 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000144
Selected probe(set): 205565_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000144 (205565_s_at) across 5392 perturbations tested by GENEVESTIGATOR:

LPS study 4 / mock treated MONO-MAC-6 cell sample

Relative Expression (log2-ratio):-4.2476215
Number of Samples:2 / 2
Experimental LPS study 4
MONO-MAC-6 (MM6) cells were treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control mock treated MONO-MAC-6 cell sample
MONO-MAC-6 (MM6) cells mock treated.

LPS study 4 (shRNA cycT1) / cycT1 depletion study 2 (shRNA)

Relative Expression (log2-ratio):-4.225624
Number of Samples:2 / 2
Experimental LPS study 4 (shRNA cycT1)
MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control cycT1 depletion study 2 (shRNA)
MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then mock treated.

LPS study 4 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample

Relative Expression (log2-ratio):-3.7178297
Number of Samples:2 / 2
Experimental LPS study 4 (shRNA contr.)
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control mock treated / transduced MONO-MAC-6 cell sample
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated.

tumor supernatant activation study 3 / memory T-cell activation study 1

Relative Expression (log2-ratio):-2.7925034
Number of Samples:4 / 3
Experimental tumor supernatant activation study 3
Memory (CD45RA-) CD4+ T cells isolated from peripheral blood of female healthy donors were incubated for 24 hours in 1:1 mix of tumor supernatant from primary invasive breast ductal carcinoma and X-VIVO 20 medium supplemented with antiCD3/CD28 beads, before harvest for RNA isolation. The tumor supernatant was prepared as followed: fresh surgical specimen was dissociated in X-VIVO 20 medium by GentleMACS dissociator and the resulting suspension was clarified by centrifugation for 15min at 13'000 g. ATC code:---
Control memory T-cell activation study 1
Memory (CD45RA-) CD4+ T-cells isolated from peripheral blood of healthy female donors were activated with anti-CD3/CD28 beads for 24hrs.

colorectal cancer study 43 (metastase; brain) / colorectal cancer study 43 (metastase; lung)

Relative Expression (log2-ratio):-2.6055527
Number of Samples:2 / 5
Experimental colorectal cancer study 43 (metastase; brain)
Metastatic tumor tissue obtained from the brain of patients with primary colorectal adenocarcinoma.
Control colorectal cancer study 43 (metastase; lung)
Metastatic tumor tissue obtained from the lung of patients with primary colon adenocarcinoma.

Friedreich's ataxia study 1 / untreated normal LCL sample

Relative Expression (log2-ratio):-2.5964985
Number of Samples:3 / 3
Experimental Friedreich's ataxia study 1
Untreated lymphoblastoid cells from a patient with Freidriech's Ataxia (FRDA; Coriell repository ID: GM15850). The patient carries homozygous GAA expansion in the FXN (frataxin) gene with alleles of approximately 650 and 1030 repeats. Clinical image: ataxia, scoliosis, hypertrophic cardiomyopathy, slurred speech.
Control untreated normal LCL sample
Untreated lymphoblastoid cells from normal healthy subject, a brother of a patient with Friedreich's ataxia (Coriell repository ID: GM15851).

precursor-B-ALL study 1 (t(12;21)(p12,q22)) / normal bone marrow sample

Relative Expression (log2-ratio):-2.5660868
Number of Samples:58 / 74
Experimental precursor-B-ALL study 1 (t(12;21)(p12,q22))
Bone marrow samples of patients with precursor B-ALL (t(12;21)(p12,q22)/TEL-AML1).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

frataxin polyamide study 1 (FRDA; match) / frataxin polyamide study 4 (match)

Relative Expression (log2-ratio):-2.42669
Number of Samples:3 / 3
Experimental frataxin polyamide study 1 (FRDA; match)
Lymphoblastoid cells derived from a patient with Freidriech's Ataxia (FRDA, Coriell repository ID: GM15850) were incubated with the match polyamide (FA1) targeting FXN (frataxin) at 1uM for 7days prior to RNA purification and microarray analysis. The patient carries homozygous GAA expansion in the FXN (frataxin) gene with alleles of approximately 650 and 1030 repeats. Clinical image: ataxia, scoliosis, hypertrophic cardiomyopathy, slurred speech.
Control frataxin polyamide study 4 (match)
Lymphoblastoid cells derived from normal healthy subject (Coriell repository ID: GM15851) were incubated with the match polyamide (FA1) targeting FXN (frataxin) at 1uM for 7days prior to RNA purification and microarray analysis.

brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample

Relative Expression (log2-ratio):-2.4081812
Number of Samples:2 / 3
Experimental brefeldin A study 1 (0.5ug/ml; p53HCT116)
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated p53HCT116 cell sample
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

precursor-B-ALL study 3 (TEL-AML1) / precursor-B-ALL study 3 (MLL-rearranged)

Relative Expression (log2-ratio):-2.3734531
Number of Samples:15 / 5
Experimental precursor-B-ALL study 3 (TEL-AML1)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(12;21)(p13,q22)/TEL-AML1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control precursor-B-ALL study 3 (MLL-rearranged)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).